Literature DB >> 18838480

Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts.

Ghulam J Mufti1, John M Bennett, Jean Goasguen, Barbara J Bain, Irith Baumann, Richard Brunning, Mario Cazzola, Pierre Fenaux, Ulrich Germing, Eva Hellström-Lindberg, Itsuro Jinnai, Atsushi Manabe, Akira Matsuda, Charlotte M Niemeyer, Guillermo Sanz, Masao Tomonaga, Teresa Vallespi, Ayami Yoshimi.   

Abstract

The classification of myelodysplastic syndromes is based on the morphological criteria proposed by the French-American-British (FAB) and World Health Organization (WHO) groups. Accurate enumeration of blast cells, although essential for diagnosis of myelodysplastic syndrome and for assignment to prognostic groups, is often difficult, due to imprecise criteria for the morphological definition of blasts and promyelocytes. An International Working Group on Morphology of Myelodysplastic Syndrome (IWGM-MDS) of hematopathologists and hematologists expert in the field of myelodysplastic syndrome reviewed the morphological features of bone marrows from all subtypes of myelodysplastic syndrome and agreed on a set of recommendations, including recommendations for the definition and enumeration of blast cells and ring sideroblasts. It is recommended that (1) agranular or granular blast cells be defined (replacing the previous type I, II and III blasts), (2) dysplastic promyelocytes be distinguished from cytologically normal promyelocytes and from granular blast cells, (3) sufficient cells be counted to give a precise blast percentage, particularly at thresholds that are important for diagnosis or prognosis and (4) ring sideroblasts be defined as erythroblasts in which there are a minimum of 5 siderotic granules covering at least a third of the nuclear circumference. Clear definitions and a differential count of a sufficient number of cells is likely to improve precision in the diagnosis and classification of myelodysplastic syndrome. Recommendations should be applied in the context of the WHO classification.

Entities:  

Mesh:

Year:  2008        PMID: 18838480     DOI: 10.3324/haematol.13405

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  75 in total

1.  When splicing turns bad.

Authors:  Jan Cools
Journal:  Haematologica       Date:  2012-01       Impact factor: 9.941

2.  Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors.

Authors:  Stefani Parmentier; Johannes Schetelig; Kerstin Lorenz; Michael Kramer; Robin Ireland; Ulrich Schuler; Rainer Ordemann; Gabi Rall; Markus Schaich; Martin Bornhäuser; Gerhard Ehninger; Frank Kroschinsky
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

3.  Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.

Authors:  Matteo G Della Porta; Cristina Picone; Cristiana Pascutto; Luca Malcovati; Hideto Tamura; Hiroshi Handa; Magdalena Czader; Sylvie Freeman; Paresh Vyas; Anna Porwit; Leonie Saft; Theresia M Westers; Canan Alhan; Claudia Cali; Arjan A van de Loosdrecht; Kiyoyuki Ogata
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 4.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

5.  Linezolid induces ring sideroblasts.

Authors:  Christophe Willekens; Florent Dumezy; Thomas Boyer; Aline Renneville; Julien Rossignol; Céline Berthon; Angélique Cotteau-Leroy; Lotfi Mehiaoui; Bruno Quesnel; Claude Preudhomme
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

6.  Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity.

Authors:  M V Ramana Reddy; Padmavathi Venkatapuram; Muralidhar R Mallireddigari; Venkat R Pallela; Stephen C Cosenza; Kimberly A Robell; Balaiah Akula; Benjamin S Hoffman; E Premkumar Reddy
Journal:  J Med Chem       Date:  2011-08-17       Impact factor: 7.446

7.  Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome.

Authors:  Mario Cazzola
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

8.  Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.

Authors:  M G Della Porta; E Travaglino; E Boveri; M Ponzoni; L Malcovati; E Papaemmanuil; G M Rigolin; C Pascutto; G Croci; U Gianelli; R Milani; I Ambaglio; C Elena; M Ubezio; M C Da Via'; E Bono; D Pietra; F Quaglia; R Bastia; V Ferretti; A Cuneo; E Morra; P J Campbell; A Orazi; R Invernizzi; M Cazzola
Journal:  Leukemia       Date:  2014-05-20       Impact factor: 11.528

9.  Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.

Authors:  Esther A Obeng; Ryan J Chappell; Michael Seiler; Michelle C Chen; Dean R Campagna; Paul J Schmidt; Rebekka K Schneider; Allegra M Lord; Lili Wang; Rutendo G Gambe; Marie E McConkey; Abdullah M Ali; Azra Raza; Lihua Yu; Silvia Buonamici; Peter G Smith; Ann Mullally; Catherine J Wu; Mark D Fleming; Benjamin L Ebert
Journal:  Cancer Cell       Date:  2016-09-12       Impact factor: 31.743

10.  Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.

Authors:  Leonor Senent; Leonor Arenillas; Elisa Luño; Juan C Ruiz; Guillermo Sanz; Lourdes Florensa
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.